+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID07117435

Study of Paclitaxel Cationic Liposome Delivered by Liver Artery with Systemic Therapy as First Treatment for Colorectal Cancer Spread to Liver

Led by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Updated on 2025-08-12

7

Participants Needed

1

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of hepatic arterial infusion of paclitaxel cationic liposome combined with systemic therapy as a first treatment for colorectal liver metastases. This phase IbIII, randomized, multicenter study aims to find the best dose of this infusion treatment and then compare its results with standard systemic therapy. The study focuses on patients with inoperable colorectal liver metastases who have not received prior systemic treatment for their metastatic disease or have progressed after previous local therapies. In the first phase Phase Ib, paclitaxel cationic liposome is given through a catheter directly into the liver artery on Day 15 of each 3-week cycle, starting with low doses and gradually increasing to find the recommended dose for Phase III. In Phase III, participants are randomly assigned to receive either the hepatic arterial infusion of paclitaxel cationic liposome plus systemic therapy Oxaliplatin, Capecitabine, with or without Bevacizumab or systemic therapy alone as first-line treatment. The systemic drugs are administered on scheduled days during each 3-week cycle. Participants undergo assessments including monitoring for dose-limiting toxicities during the first 21-day cycle and evaluation of adverse events for up to about one year. Researchers also measure drug levels and study various outcomes such as tumor response, disease control, progression-free survival, and overall survival over follow-up periods extending up to three years. Laboratory tests, imaging, and physical evaluations are performed to track treatment effects and safety throughout the study duration.

CONDITIONS

Brief Title

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

Research Team

C

Clinical Trials Information Group officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here